hexenoyl group raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-09-26. Anything still debated is marked as such rather than presented as settled.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
corrosion An irreversible interfacial chemical reaction of a material, especially a metal, with its environment, which results in consumption of the material or dissolution into the material of an external component of the environment.
For services to the community in Rugby, Warwickshire. Margaret Sandra Myers. For services to the community in Sheffield, South Yorkshire. David Mynott. Volunteer, Torfaen Dementia Group. For services to People with Dementia and their Carers. Moez Kass Amali Nathu. Chief Executive, Peterborough Asylum and Refugee Community Association. For services to Refugees and Asylum Seekers in Peterborough. Robert Thomson Nellies. President, Falkland Cricket Club. For services to Cricket and to the community in Fife. Elyn Catherine Neville. For charitable services to Cancer Patients and to Cancer Services in Pembrokeshire. Margaret Alice Newell. Lately Office Manager, Privy Council Office. For Public Service, particularly during the Accession Council. Matthanee Nilavongse. For services to the community in Todmorden, West Yorkshire. William Ellis Nixon. Honorary Secretary, Social Enterprise UK. For services to Young People in the West Midlands. Uzoamaka Louisa Nwokolo. Lately Executive Officer, Department for Transport. For services to Young People. Diana Violet O'Grady. For services to the community in Arreton, Isle of Wight. Samuel Jozef Oldroyd. Chief Executive Officer, JADE Youth and Community. For services to Young People and Families in Rother Valley, South Yorkshire. Clive John Owen. Vice Chair, Aberavon Green Stars Rugby Football Club. For charitable services to Young People and to the community in Aberavon, West Glamorgan. Diane Oxley. For services to Young People and to the community in Thurcroft, South Yorkshire. Tracie Ann Pal.
== Importance == Proteomic profiling is important in the advancement of our understanding of biological processes and mechanisms of disease. It helps in pathogen identification, thereby enhancing diagnostics and vaccine development by revealing protein interactions and functions related to virulence. Protein profiling has greatly helped in the early detection of cancers by using specific proteins found in the blood plasma. Recent studies have developed proteome-based tests with a high degree of accuracy in the detection of early stage cancers, using panels of proteins that distinguish cancerous from normal samples. For example, it has recently been demonstrated that using panels of ten sex-specific proteins, early-stage cancer could be identified with up to 93% accuracy in males and 84% in females at high specificity levels.
Sources: en.wikipedia.org
Gyrification The process by which the cerebral cortex develops folds (gyri) and grooves (sulci) during brain development. Gyrification increases the surface area of the brain, allowing for greater cognitive capacity within the limited volume of the skull.
In southwestern Germany, territorial revision seemed to be a top priority since the border between the French and American occupation zones was set along the Autobahn Karlsruhe-Stuttgart-Ulm (today the A8). Article 118 stated "The division of the territory comprising Baden, Württemberg-Baden and Württemberg-Hohenzollern into Länder may be revised, without regard to the provisions of Article 29, by agreement between the Länder concerned. If no agreement is reached, the revision shall be effected by a federal law, which shall provide for an advisory referendum." Since no agreement was reached, a referendum was held on 9 December 1951 in four different voting districts, three of which approved the merger (South Baden refused but was overruled, as the result of total votes was decisive). On 25 April 1952, the three former states merged to form Baden-Württemberg.
Civil society in Pakistan is hierarchical, emphasising local cultural etiquette and traditional Islamic values. The primary family unit is the extended family, but there's a rising trend towards nuclear families due to socio-economic factors. Both men and women typically wear Shalwar Kameez; men also favour trousers, jeans, and shirts. The middle class has grown to about 35 million, with another 17 million in the upper and upper-middle classes, leading to a shift in power from rural landowners to urban elites. Festivals like Eid ul-Fitr, Eid ul-Azha, Ramadan, Christmas, Easter, Holi, and Diwali are primarily religious. Pakistan ranked 56th on the 2006 A.T. Kearney/FP Globalization Index due to increasing globalisation.
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.